Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Matrix Bound Nanovesicles
- Development stage
- Preclinical
- Lead developer
- ECM Therapeutics
- Modality
- Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Topical, Ophthalmic
01
Overview
MBV (Matrix Bound Nanovesicles) is a preclinical-stage biologic therapy being developed by ECM Therapeutics, based on technology from the Badylak Laboratory at the University of Pittsburgh. These nanovesicles are derived from the extracellular matrix (ECM) and are formulated as topical ophthalmic eye drops. MBV is designed to promote corneal healing and provide protection against environmental damage, with potential applications in post-procedural healing and dry eye disease. The mechanism involves leveraging the regenerative properties of ECM-associated signaling molecules to facilitate tissue repair and modulate the local microenvironment.
- Other names
- Matrix Bound Nanovesicles
02
Targets
NF-κB
Beyond the preview
Go deeper on Matrix Bound Nanovesicles.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Matrix Bound Nanovesicles.